The Promise of
CGRP Targeted Therapies in the Treatment and
Prevention of Migraines: What Managed Care Needs to Know in
the Evolving Treatment Paradigm
medical education activity sponsored by NAMCP and AAMCN
The Promise of CGRP Targeted Therapies in the Treatment
and Prevention of Migraines: What Managed
Care Needs to Know in the Evolving Treatment Paradigm is
a 3-part webcast series that will provide
attendees with the latest
information in the management of migraines.
By clicking on
each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.
These are archives of live webinars held between June 14, 2019 and June 27,
If you participated in any of the live webinars, you are not eligible to claim
credit from the archive of that webinar.
Each session has
its own specific valid dates
This series is supported by an educational grant
from Teva Pharmaceuticals
This activity is intended for healthcare professionals practicing in managed
CME/CNE: Complete the pre-test, listen to the audio and view the slides,
complete the post test, complete the evaluation form and hit submit. You will be
asked to enter your name and email address on the pre-test, evaluation and
post-test. If you close your internet browser without completing the post test,
you will have ONE more opportunity to complete. A score of 70% must be achieved
on the post test to receive continuing education credits. If you do not pass the
post test after two attempts, you will not be eligible to try again. Once you
complete the evaluation form and score 70% or higher on your post test, you will
automatically be given your certificate.
Migraine is a major neurological disease that affects more than 36 million men,
women and children in the US. Migraine headache is the most common type of
headache presented by patients that seek medical treatment, and the WHO has
ranked migraine in the top fifteen most disabling medical conditions. Although
approximately 38% of migraineurs need preventive therapy, only 3% to 13%
currently use it. Fortunately for patients who suffer from migraine headaches, a
new class of therapy is emerging that has shown to offer vastly improved
efficacy and safety over traditional treatment regimens. Three calcitonin
gene-related peptide (CGRP) monoclonal antibodies have recently been approved
that offer healthcare professionals a new and improved armamentarium in the
treatment and prevention of migraines.